Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to “Sell” at Wall Street Zen

Denali Therapeutics (NASDAQ:DNLI) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other research analysts also recently weighed in on the stock. UBS Group increased their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a report on Friday, August 7th. B. Riley Financial lifted their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Wedbush reiterated an “outperform” rating and issued a $26.00 price objective on shares of Denali Therapeutics in a research note on Monday, July 13th. Finally, Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $35.85.

Denali Therapeutics Price Performance

DNLI opened at $19.45 on Friday. Denali Therapeutics has a fifty-two week low of $13.75 and a fifty-two week high of $27.30. The firm has a 50-day moving average of $22.40 and a 200 day moving average of $21.84. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. The firm has a market cap of $3.11 billion, a P/E ratio of -6.85 and a beta of 1.02.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter last year, the company posted ($0.72) earnings per share. On average, research analysts expect that Denali Therapeutics will post -2.67 EPS for the current year.

Insiders Place Their Bets

In related news, insider Alexander O. Schuth sold 2,768 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total value of $64,881.92. Following the sale, the insider directly owned 278,995 shares in the company, valued at approximately $6,539,642.80. The trade was a 0.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.70% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC raised its stake in shares of Denali Therapeutics by 44.4% during the 3rd quarter. GAMMA Investing LLC now owns 2,236 shares of the company’s stock valued at $46,000 after purchasing an additional 687 shares during the period. Engineers Gate Manager LP lifted its holdings in Denali Therapeutics by 256.5% during the 2nd quarter. Engineers Gate Manager LP now owns 57,430 shares of the company’s stock worth $1,477,000 after purchasing an additional 41,320 shares in the last quarter. Integrated Wealth Concepts LLC lifted its holdings in Denali Therapeutics by 2.7% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 102,241 shares of the company’s stock worth $2,630,000 after purchasing an additional 2,687 shares in the last quarter. Allworth Financial LP lifted its holdings in Denali Therapeutics by 555.0% during the 2nd quarter. Allworth Financial LP now owns 1,834 shares of the company’s stock worth $47,000 after purchasing an additional 1,554 shares in the last quarter. Finally, Nykredit A S bought a new position in Denali Therapeutics in the 2nd quarter worth about $38,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing medicines for patients with neurodegenerative diseases. The company’s research programs address conditions involving the central nervous system, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders.

Denali’s drug-discovery approach is built around its Transport Vehicle platform, which is designed to help therapeutic molecules cross the blood-brain barrier and reach the brain.